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Teva Pharmaceutical: Generic 




The present paper represents a qualitative case study on the pharmaceutical 
company Teva, including an in-depth exploration of the company within the 
specific context of pharmaceutical industry. Being a qualitative case study in the 
business discipline, the company details regarding the shareholders, the stock 
price fluctuations in recent decades in comparison with other competitors will be 
presented. The objective of this article is to provide a thorough description of Teva, 
a global leader in the pharmaceutical industry, by assessing the evolution of the 
company considering the changes at the corporate level and in the market, like the 
appearances of new competitors. The results will contribute in providing an insight 
in how future pharma companies can avoid certain pitfalls and how they should 
reply to the market competition and different other changes on the market.
Keywords: Pharmaceutical, market access, healthcare, global industry
1. Introduction
Teva Pharmaceutical Industries Ltd. is Israel’s first and largest multinational, 
reaching a dominant position on the global level, in generic pharmaceuticals. Teva 
has humble beginnings. Established in 1901, it was created out of a family endow-
ment, immigrant loads, and a modest early investment. By 1990, it was one of the 
most prominent pharmaceutical companies in the world [1]. Teva’s global meteoric 
rise was largely due to the development and patent of COPAXONE®, a novel treat-
ment for multiple sclerosis.
Teva Pharmaceutical Industries Ltd. was one of the first companies to produce 
generic drugs and now it is one of the largest pharmaceutical companies in the 
world, with 16,000 products related to generics, novel drugs, and over-the-counter 
medications. Teva had been active in 60 countries internationally and supplied 
drugs to 200 million people worldwide. Manufacturing, research, and marketing 
sites were largely located in Israel, North America, and Europe.
The company had staff strength of 60,000 people, of which 6,500 were based in 
Israel. Since 1976, Teva has had eight chief executive officers (Figure 1). The year 1976 
was a turning point for the company as Teva, Zori, and Assia united to create Teva 
Pharmaceutical Industries Ltd. It was a period of consolidation for the business [2].
The pharma industry suffered significant transformations over the last decades 
and a thorough analysis of how these changes impacted Teva company are worthy 
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of study. Also, it is important to understand the new competitors from emerging 
markets, which are adopting aggressive tactics on the market. The present research 
describes an analysis of the case study on Teva company in the context of pharma 
industry, having as purpose to provide an insight in how future pharma companies 
can avoid certain pitfalls and how they should reply to the market competition and 
different other changes on the market (Figure 2).
2. Literature review
2.1 Company’s values
With a mission to be a global leader in generics and biopharmaceutical, improv-
ing the lives of patients worldwide, Teva’s core values were centred on corporate 
Figure 1. 
Teva C.E.O.s since 1976.
Figure 2. 
Teva’s logo, describing Teva’s values.
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responsibility and transparency. During its initial successful decades, Teva con-
sciously stressed a culture of employee satisfaction, and its message was that of a 
consumer brand to be trusted.
Teva emphasized the importance of drug safety, collaborations, health initia-
tives, and innovative research. The company had committed to various socio-
economic initiatives, including donations, human rights, diversity, inclusion, 
occupational health, and safety, as well as the environment and pharmaceutical 
drugs [3].
2.2 History
The Teva production plant was established in Jerusalem on May 1, 1935, located 
in the neighborhood of Bayit Vegan. The factory was built with an investment of 
4,900 pounds sterling, partially from the family endowment and partially from 
loans made by German immigrants. The immigrants wanted to support fellow 
German, Günther Friedlander, who was a pharmacist and botanist.
Banker Dr. Alfred Feuchtwanger became a partner in Teva when he funded 
a credit shortage in the company. He held a 33% share of Teva. In 1951, 
Dr. Feuchtwanger initiated Teva’s initial public offering and entrance into the 
Tel Aviv Stock Exchange as a publicly listed and traded company.
During World War II, the factory supplied medicines to the Allied forces, in 
particular, to the British army in the Middle East. Sir Alan Gordon Cunningham, 
Colonial Minister and head of the British Mandate, visited the factory on behalf 
of the Secretary of State for the Colonies. His visit to the Teva factory significantly 
jumpstarted its reputation in the pharmaceutical industry.
In 1959, the pharmaceutical branch of the Israeli Manufacturer’s Association 
conducted a survey among Israeli pharmaceutical companies, and the Teva plant 
in Jerusalem was ranked first. The results of the survey showed that the market 
approved of and supported Teva products, many of which were developed by Dr. 
Friedlander and the factory staff. The workers felt appreciated for their initiative 
and ideas. They took pride in their work and performed their tasks with strict 
execution.
In 1971, the Teva plant moved from Bayit Vegan to the industrial park in Har 
Hozvim. It was the first scientific factory that was established in Kiryat Atirot. 
Teva has expanded its operations over the years. For instance, in 1982, Teva 
received F.D.A. approval for its Kfar Saba plant in central Israel, which allowed it 
to market its generic drugs in the United States. The factories of Teva enabled the 
business to transform into a powerhouse drug maker. In 2019, the Kfar Saba plant 
of Teva received an F.D.A. approval stamp for the manufacturing of migraine 
drugs [4].
2.3 The company’s main products
Regarding the commercialized products, the drugs produced by Teva can be 
used for migraines, pain management, cancer, and supportive care, and respira-
tory disorders. Some of the common generic drugs of the company are Alvimopan 
Capsules, Brinzolamide Ophthalmic Suspension, Colchicine Tablets, U.S.P., 
Dimethyl Fumarate Delayed-Release Capsules, Efavirenz, Emtricitabine, and 
Tenofovir Disoproxil Fumarate Tablets, etc. [5].
The company expanded into the treatment of a wide variety of disease types 
while simultaneously developing generic drugs. The goal was to provide faster and 
better solutions for patients battling various diseases. From a business perspective, 
Teva’s strategy was to increase drug production to generate higher revenue.
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In the mid-1990s, Teva introduced a novel drug called COPAXONE®, to 
treat multiple sclerosis. The drug was developed by a team of researchers at the 
Weizmann Institute of Science and was considered the world’s best treatment 
against the condition. COPAXONE® received the United States Food and Drug 
Authority (F.D.A.) approval in 1996 and was regarded as one of the greatest 
achievements of Israel’s scientific efforts.
This invention transformed Teva from a company that produced generic drugs 
to one that produced novel treatments. Since 2015, COPAXONE® was marketed 
to more than 50 countries worldwide. Teva’s revenue from worldwide drug sales 
reached $4.2 billion, roughly 21% of the company’s total revenue.
Another novel drug produced by Teva called Azilect was intended to treat 
Parkinson’s disease. Teva launched the drug in Israel in 2005. A year later, the drug 
was launched and marketed in the United States. Teva discovered that Azilect was 
the only drug in the world that could treat the symptoms of Parkinson’s disease and 
delay the physical deterioration due to the disease. Azilect has been sold in more 
than 45 countries around the world. In 2010, sales revenue for Azilect was $318 
million.
At the end of 2016, Teva’s novel drug portfolio was worth hundreds of millions 
of dollars. Considerable investments in R&D were critical to developing new novel 
drugs and maintaining Teva’s current portfolio of novel drugs.
Patent protection has been an important tool for Teva to safeguard its innovation 
as well as to recoup the R&D invests in drug development. Various companies had 
tried to launch drugs in order to compete with COPAXONE®. In June 2015, the U.S. 
Federal Court of Appeals ruled that Teva’s patent of its 20 mg dose of COPAXONE® 
was expired.
Teva’s losses continued in 2017, as the U.S. Patent Commission in the Delaware 
District Court filed a motion to revoke the exclusivity of the patent from Teva that 
had accrued them $49 billion in revenue. This caused the company’s stock to decline 
about 50 percent in 12 months’ time. Additionally, the Federal Court of Appeals 
filed a request to cancel the validity of one of the company’s patents for the lung 
cancer drug Alimta that earned the company $1.1 billion in 2016.
Teva had been looking at introducing a novel migraine drug to be a replace-
ment of sorts for COPAXONE®. This new drug hoped to treat various iterations 
of migraines. Teva has introduced AJOVY, which is a pre-filled injection for the 
prophylaxis of migraines in adults. It received a nod from European Medicines 
Agency’s Committee for Medicinal Products for Human Use in 2019 [6]. Despite 
patent challenges in the United States, in December 2015, the European Patent 
Office approved Teva’s patent for the 40 mg dose of COPAXONE® until 2030.
3. Research method
To understand the evolution of a company in time, it is important to analyze the 
key factors which contribute to the success or to the fall of a company. The present 
paper is based on a qualitative research, aiming to provide an in-depth understand-
ing on the correlation between the internal and external changes and the company’s 
evolution.
According to Baskarada [7], the case study method is the most widely used 
method in academia for researchers interested in qualitative research, Baskarada [7] 
emphasizing the need to have a succinct guideline that can be practically followed.
This research presents a qualitative case study on Teva company in the context 
of pharma industry. Baxter and Jack [8] define a qualitative case study as a research 
methodology that helps in exploration of a phenomenon within some particular 
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context through various data sources, and it undertakes the exploration through 
variety of lenses in order to reveal multiple facets of the phenomenon. In the case 
of Teva company, the used data sources are business reports, news media, as well 
as specialized articles on pharmaceutical industries. The company is analyzed from 
multiple facets like the evolution of the stock price, the corporate decisions, the 
appearance of new competitors on the market and how the company’s revenues 
have been affected.
According to Yazan [9], in qualitative research, case study is one of the fre-
quently used methodologies, in which a real-time phenomenon is explored within 
its naturally occurring context, with the consideration that context will create a 
difference [10]. In the present case, the real-time phenomenon is the historical 
evolution of the Teva company with the consideration that the context of the overall 
pharmaceutical industry plays an important part in this evolution.
The considered phases of the chosen methodology are the same as the one pro-
posed by Rashid et al. [11] and they are the following: the foundation phase (ana-
lyze of what is relevant in assessing the success of Teva company in the context of 
pharma industry), prefield phase (deciding on the factors which will be measured, 
the case study protocol), field phase (in this case, gathering the relevant data from 
trustworthy resources), reporting phase (reporting the findings).
The factors which help in assessing the evolution of Teva company are the com-
petitors, the company’s business strategy, the stock performance and the company’s 
overall performance. By analyzing these factors and reporting some of the quantita-




Teva has several competitors in the global market, like Momenta 
Pharmaceuticals, Mylan, Synthon, Unipharm and Rafa. Another name worth 
mentioning is Allergan, which, in 2015, became the largest shareholder of Teva after 
Teva acquired Allergan’s generic pharmaceutical division.
One of the main products of Momenta Pharmaceuticals is Glatopa®, a generic 
form of COPAXONE®. In 2015 Glatopa® was approved by the US FDA and 
launched in the United States. Momenta Pharmaceuticals collaborated with Sandoz, 
a Novartis company, to produce Glatopa®. The intent was for Glatopa® to replace 
Teva’s 40 mg dose of COPAXONE® [12].
The multinational drug development company, Mylan, was registered and 
based in the Netherlands, with branches in the U.K. and Pennsylvania. Until 2007, 
the American branch of Mylan only operated in the domestic market. However, 
after Mylan acquired German drug company Merck, and the Indian Laboratories of 
Matrix, Mylan became the second-largest generic drug company in the world, after 
Teva. Mylan started marketing their version of the 40 mg dose of COPAXONE® in 
October 2017 [13].
The Dutch company Synthon, is an international pharmaceutical company and 
one of the leaders in the field of generic medicines. In 2017, Synthon announced 
that it had successfully conducted clinical trials in order to prove that its glat-
iramer acetate (sold as Remurel by Alvogen) provided the same therapeutic 
benefit as Teva’s 40 mg COPAXONE®. Synthon received the European Medical 




Regarding the key competitors in the domestic market, Unipharm and Rafa are 
worth mentioning. Unipharm, had been developing and marketing generic drugs 
since 1975. Founded by pharmacist Zvulun Tomer, the company was a pioneer in 
the generic drugs force. Unipharm’s drugs targeted the treatment of a wide range 
of diseases and symptoms such as mental health, heart health, sleep, Alzheimer’s, 
infectious diseases, urology, eyes, and more. In 2017, Unipharm launched a new 
plant in Mavo Carmel. At this manufacturing plant, Unipharm introduced new 
technologies and development processes to achieve production efficiencies and 
cost savings in generic drug manufacturing [15]. It uses innovative approaches to 
act as a one-stop solution for health manufacturing needs and thus poses chal-
lenges to Teva.
Rafa was founded in 1937 and is one of the leading pharmaceutical companies 
in the country. The company specialized in the marketing, manufacturing, and 
distributing of novel and generic drugs, prescription drugs, over-the-counter 
drugs, as well as therapeutic products. Rafa products were marketed to all Israeli 
health institutions, such as public and private hospitals, clinics, health clinics, 
and more, serving a wide range of ages in the population, from infants to the 
elderly [16]. The company focuses on research activities to introduce the latest 
drugs and therapies relating to different conditions and thus poses a challenge 
for Teva [17].
4.2 The business strategy
Since the 2000s, Teva had embarked on an acquisition strategy – buying over 
large generic drug companies to create value for the company. Some acquisitions 
seemed initially successful but proved otherwise later. Other acquisitions lacked 
clear plans. When Teva acquired U.S. drug company Cephalon in October 2011, 
Cephalon’s R&D team took over the development of the anti-depression drug. 
Within a year, the R&D employees were laid off.
The acquisitions resulted in significant short-term financial gains because stock 
prices could be raised through acquisitions. Chief executives of that period had 
focused on creating shareholder value through mergers and acquisitions in the 
pharmaceutical market, rather than focusing their energy on their drug clientele 
and patients. They also channeled investments away from the research and develop-
ment of drugs such as COPAXONE®.
4.3 Stock performance
Teva had a “dual stock,” or a stock that traded in two trading areas: in the home 
country of the company, and in the stock exchange of another large country. Teva’s 
dual stock was traded on the Tel Aviv Stock Exchange as well as the New York Stock 
Exchange.
At the beginning of the 2000s, Teva’s share rose 20 times, which significantly 
impacted the Tel Aviv Stock Exchange. Investment in Teva had become extremely 
popular and was even referred to as the “people’s share.” However, Teva stock also 
experienced sharp declines during 1998, the middle of 2004, and after the publica-
tion of negative reports in 2006. A financial commentator at one point even said, 
the public suddenly understands that “Teva is also a share.”
From the beginning of 2014 until the middle of 2015, Teva’s share price  
almost doubled, but by the end of 2016, it returned to the level that it was in  
early 2014. In May 2017, Teva’s share dropped to a level that it has not been 
since 2005.
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4.4 Teva’s overall performance
Since the end of 2015, Teva’s shares are down by 64%, which has erased more 
than $40 billion in market capitalization [18]. The company’s worsening perfor-
mance led to a wave of layoffs. Teva cut 14,000 jobs worldwide, which was more than 
25 percent of the company’s international workforce. According to Teva, it plans to 
lay off 1,750 employees, and that’s just the beginning [19]. The layoffs will occur as 
a result of the closure or sale of a significant number of R&D sites, headquarters, 
offices, and a number of the company’s geographical divisions will also be reduced.
By the end of 2017, Teva closed or sold six plants. This was followed by the 
closure of another nine plants in 2018.
The company’s two plants in Jerusalem, which employed 1,100 employees, have 
been closed, the factory in Kiryat Shmona sold, the R&D center in Netanya, which 
employed 350, people has also closed as of 2019 [20].
In addition, Teva ceased operations at the global logistics center S.L.A. from the 
Shoham Industrial Area, even though it employed 700 people [21].
While on the one hand, the reduction plan raised the value of the stock by 
creating the illusion of improvement, it damaged employee and customer trust and 
further contributed to the deterioration of the company’s shares.
In 2019, Teva’s total revenue fell by 8% to $16.9 million, which was a decrease 
of 8% as compared to 2018. This decline was mainly due to various reasons like 
the generic competition to COPAXONE®, a decline in revenues from U.S. generics 
business, BENDEKA®/TREANDA®, and Japan. However, this decline was par-
tially offset by higher revenues from AUSTEDO, AJOVY, and QVAR® in the United 
States. COPAXONE® accounted for 11% of Teva’s North America revenue from 
October to November 2019 [22].
5. Discussion
By combining the above-mentioned factors, a broad picture of the company’s 
evolution can be painted.
Things took a downturn in the 2000s when Teva embarked on a strategy to 
create shareholder value through mergers and acquisitions. When Teva acquired 
U.S. drug company Cephalon in October 2011, Cephalon’s R&D team took over the 
development of the anti-depression drug. Within a year, the R&D employees were 
laid off. The acquisitions resulted in significant short-term financial gains because 
stock prices could be raised through acquisitions. Chief executives of that period 
had focused on creating shareholder value through mergers and acquisitions in the 
pharmaceutical market, rather than focusing their energy on their drug clientele 
and patients. They also channeled investments away from the research and devel-
opment of drugs such as COPAXONE®. Teva’s reputation as an innovative and 
entrepreneurial Israeli company with a heart for its employees seemed to have lost 
its way (Figure 3).
In 2015, Teva’s competitor, Allergan, became the largest shareholder of Teva 
after Teva acquired Allergan’s generic pharmaceutical division. This resulted in 
much unhappiness among other shareholders, causing a corporate crisis. The other 
shareholders of the business were dissatisfied as the two leading generic businesses 
came together, and their fundamental needs and expectations overshadowed the 
needs of other shareholders [23].
After the U.S. Federal Court of Appeals ruled in 2015 that Teva’s patent of its 




Areas of care treated by Teva. (Sources: 1Teva treatment for migraine, https://www.teva.co.il/Treatment-area/
Migraine/, date accessed: 28 February 2020. 2Teva launches AJOVY for the treatment of migraine with the 
YpsoMate autoinjector from Ypsomed, https://www.ypsomed.com/fr-CA/derniere-nouvelles/news-reader-detail-
page/teva-launches-ajovy-for-the-treatment-of-migraine-with-the-ypsomate-autoinjector-from-ypsomed.
html#:~:text=AJOVY®%20(fremanezumab%2Dvfrm),is%20affected%20by%20migraine%20worldwide, 
date accessed: 28 February 2020. 3Teva treatment for pain, https://www.teva.co.il/Treatment-area/Pain/, date 
accessed: 28 February 2020. 4Teva treatment for CNS, https://www.teva.co.il/Treatment-area/Central-Nervous-
System/, date accessed: 28 February 2020. 5Teva treatment for cancer, https://www.teva.co.il/Treatment-area/
Oncology/, date accessed: 28 February 2020. 6Teva treatment for breathing, www.teva.co.il/Treatment-area/
BreathLobby/, date accessed: 28 February 2020. Teva Pharmaceutical Industries Limited, https://www.
annualreports.com/HostedData/AnnualReports/PDF/NYSE_TEVA_2019.pdf, date accessed: 28 February 2020.)
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versions and the profitability of COPAXONE® eroded, and Teva’s market share 
plunged. With the launch of Glatopa®, Teva had expected it to reduce Teva’s 
revenue by 18% to 4.7 billion as well as further eroding prices [24]. This increased 
the competition of COPAXONE® significantly. Also, the competition generated 
by Mylan’s generic version, sparked a competitive price war leading to Teva’s US 
COPAXONE® revenue to fall by 20 percent (Figure 4). Regarding Synthon, one hit 
was when Synthon was accepted in European markets. Even though the European 
market was not the most important market for COPAXONE®, Teva had until then 
enjoyed patent protection and avoided competition. Synthon’s announcement came 
just a few days after Mylan launched the 40 mg and 20 mg versions of glatiramer 
acetate in the United States [14].
Teva’s troubles continued to mount. Its share value was reduced in the 
indices due to stock exchange reform. Teva was also denied a critical patent 
application which eroded the profitability of the flagship drug COPAXONE®. 
COPAXONE®faced growing competition after parallel pharmaceutical companies 
launched their generic versions in 2016, which triggered a precipitous decrease in 
Teva’s market share (Figure 5).
One of the main reasons for Teva’s losses is a result of being entirely depen-
dent on the sales of one of the company’s primary drugs, Copaxone, used as the 
Figure 4. 





accessed: 28 February 2020.)
Figure 5. 
Source: Zacks, Generic Industry on Path to Recovery: 3 Hot Picks for 2019, https://www.nasdaq.com/articles/




Annual revenue of Teva Pharmaceuticals industries. (Source: Revenue of Teva Pharmaceutical Industries from 
2006 to 2020, https://www.statista.com/statistics/272542/teva-pharmaceutical-industries-net-sales-since-2006/, 
date accessed: 28 February 2020.)
treatment for M.S. This puts Teva in a weak position because any drop in drug sales 
can and will have a negative impact on the company.
When Schultz joined the company, Teva’s debt was $40 billion. Teva had also 
begun a process of significant streamlining, which included laying off about 25 
percent of its employees, or roughly 14,000 people, and 1,750 in Israel alone. Teva 
had lost more than half its market value, with plans underway to leave 45 countries 
before the year is out. It is currently difficult to assess what can be done so that Teva 
can rebuild its reputation (Figure 6).
The acquisitions resulted in significant short-term financial gains because stock 
prices could be raised through acquisitions. Chief executives of that period had 
Figure 6. 
Teva’s stock performance. (Source: Teva Pharmaceutical Industries Limited, https://finance.yahoo.com/chart/
TEVA, date accessed: 28 February 2020.)
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focused on creating shareholder value through mergers and acquisitions in the 
pharmaceutical market, rather than focusing their energy on their drug clientele 
and patients. They also channeled investments away from the research and devel-
opment of drugs such as COPAXONE®. Teva’s reputation as an innovative and 
entrepreneurial Israeli company with a heart for its employees seemed to have lost 
its way (Figure 7).
In May 2017, Teva’s share dropped to a level that it has not been since 2005; the 
decline was due to investors’ concerns that in June 2017, Mylan would receive autho-
rization to initiate the marketing of a generic version of Teva’s profitable 40 mg 
COPAXONE® in the United States.
In the last decade, Teva has spent $70 billion on giant acquisitions, Cephalon 
and Actavis, and for that reason, it is expected that its value to be minimally $70 
billion, but in reality, it is about half of that, and its share has plummeted more than 
the rest of the sector. The cutting of spending was not large enough to justify the 
acquisition.
In 2019, Teva’s total revenue fell by 8% to $16.9 million, which was a decrease 
of 8% as compared to 2018. This decline was mainly due to various reasons like 
the generic competition to COPAXONE®, a decline in revenues from U.S. generics 
business, BENDEKA®/TREANDA®, and Japan. However, this decline was par-
tially offset by higher revenues from AUSTEDO, AJOVY, and QVAR® in the United 
States. COPAXONE® accounted for 11% of Teva’s North America revenue from 
October to November 2019 [22].
In spite of the many difficulties the company faced in the last decades, there 
is still the possibility that the company can rebalance again and learn from its 
mistakes. Teva is still a major pharmaceutical company that offers a broad range 
of drugs in the global market setting. It has been showcasing consistent perfor-
mance and contributing to improve the health outcome of the general public. The 
firm’s strategy plays a cardinal role in influencing its contribution to the dynamic 
industry.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
12
Healthcare Access
[1] Reference for Business (2020). Teva 
Pharmaceutical Industries Ltd. - 
Company Profile, Information, Business 
Description, History, Background 
Information on Teva Pharmaceutical 




(accessed on February 28, 2020).
[2] Teva Pharm 1 (2020). Improving 
health since 1901. Teva Pharm, 
URL:https://www.tevapharm.com/
our-company/teva-history/#46361253 
(accessed on February 28, 2020).
[3] Teva Pharm 2 (2020). Teva Core 
Values. Teva Pharm, URL: https://www.
tevapharm.com/our-company/our-
values/ (accessed on February 28, 2020).
[4] Zomer, N. (2019). Teva’s Israeli Plant 
Receives FDA Stamp of Approval for 




(accessed on February 28, 2020).
[5] Teva USA (2020). Generic medicines. 
Teva USA, URL: https://www.tevausa.
com/our-products/article-pages/
article-generic-medicine/ (accessed on 
February 28, 2020).
[6] Maggie Lynch, M. (2019). EU 
approval for Teva’s quarterly dosed 







to%20the%20receptor. (accessed on 
February 28, 2020).
[7] Baskarada, S. (2014). Qualitative case 
study guidelines. The Qualitative Report, 
19, 1-25.
[8] Baxter, P., Jack, S. (2008). Qualitative 
case study methodology: Study design and 
implementation for novice researchers. The 
Qualitative Report, 13, 544-559.
[9] Yazan, B. (2015). Three approaches to 
case study methods in education: Yin, 
Merriam, and Stake. The Qualitative 
Report, 20, 134-152.
[10] Kaarbo, J., Beasley, R. K. (1999). A 
practical guide to the comparative case 
study method in political psychology. 
Political Psychology, 20, 369-391.
[11] Rashid, Y., Rashid, A., Warraich, 
M.A., Sabir, S. and Waseem, A. (2019). 
Case Study Method: A Step-by-Step Guide 
for Business Researchers. Computer 
Science. International Journal of 
Qualitative Methods. 
DOI:10.1177/1609406919862424.
[12] National Multiple Sclerosis Society 
(2015). An FDA Approved Generic Form 
of COPAXONE® (Glatiramer Acetate) 
For Relapsing MS Called Glatopa is 
Launched in the US. National Multiple 




(accessed on February 28, 2020).
[13] Mylan, N.V. (2017). Mylan 
Announces U.S. FDA Approval of First 
Generic for Copaxone® 40 mg/mL 
3-Times-a-Week and May Be Eligible for 







on February 28, 2020).
[14] Macdonald, G. (2017). Synton’s 
generic version of Copaxone 40mg 









in-Europe (accessed on February 
28, 2020).
[15] Unipharm (2021). News and 
Updates. Unipharm. URL: http://
unipharm.co.il/news-updates/?lang=en 
(accessed on February 28, 2020).
[16] Rafa (2021). A career in healing. 
Rafa. URL: https://www.rafa.co.il/ 
(accessed on February 28, 2020).
[17] Bloomberg (2021). Rafael 
Pharmaceuticals Inc. Bloomberg. URL: 
https://www.bloomberg.com/profile/
company/1692961D:US (accessed on 
February 28, 2020).
[18] Roland, D. and Jones, R. (2017). 
Teva Pharmaceutical’s Stock Tumbles on 
Outlook. Wall Street Journal. URL: 
https://www.wsj.com/articles/generic-
competition-roils-teva-1501773117 
(accessed on February 28, 2020).
[19] BBC (2017). Teva Pharmaceuticals: 
Israeli drugmaker to cut 14,000 jobs. BBC. 
URL: https://www.bbc.com/news/
world-middle-east-42356115 (accessed 
on February 28, 2020).
[20] Greenberg, T. (2019). Teva to Sell 
Northern Israeli Facility to Private Equity 
Fund FIMI. Calcalistech. URL: https://
www.calcalistech.com/ctech/
articles/0,7340,L-3755808,00.html 
(accessed on February 28, 2020).
[21] Liu, A. (2019). Teva sheds logistics 
center for $127M after 2 about-faces. 
Fierce Pharma. URL: https://www.
fiercepharma.com/pharma/teva-sheds-
logistics-center-for-127m-after-2-years-
2-about-faces (accessed on February 
28, 2020).
[22] Teva (2019). Teva Reports Fourth 
Quarter and Full Year 2019 Financial 
Results. Teva Press Release. URL: 
https://s24.q4cdn.com/720828402/files/
doc_financials/2019/q4/Q4.2019_
PR.wtables_Final.pdf (accessed on 
February 28, 2020).
[23] Business Wire (2020). Teva 
Completes Acquisition of Actavis 




Generics (accessed on February 
28, 2020).
[24] Cohen, T., Rabinovitch, A. (2018). 
Teva Pharm shares sink as sales forecast 




(accessed on February 28, 2020).
